Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases
The enzymatic activity of CD26/DPP4 (dipeptidyl peptidase 4/DPP4) is highlighted in multiple studies to play a vital role in glucose metabolism by cleaving and inactivating the incretins glucagon-like peptide-1 (GLP) and gastric inhibitory protein (GIP). A large number of studies demonstrate that CD...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/27/14/4498 |
| _version_ | 1797416751467593728 |
|---|---|
| author | Xiaopeng Hu Xisheng Wang Xingkui Xue |
| author_facet | Xiaopeng Hu Xisheng Wang Xingkui Xue |
| author_sort | Xiaopeng Hu |
| collection | DOAJ |
| description | The enzymatic activity of CD26/DPP4 (dipeptidyl peptidase 4/DPP4) is highlighted in multiple studies to play a vital role in glucose metabolism by cleaving and inactivating the incretins glucagon-like peptide-1 (GLP) and gastric inhibitory protein (GIP). A large number of studies demonstrate that CD26 also plays an integral role in the immune system, particularly in T cell activation. CD26 is extensively expressed in immune cells, such as T cells, B cells, NK cells, dendritic cells, and macrophages. The enzymatic activity of CD26 cleaves and regulates numerous chomokines and cytokines. CD26 inhibitors have been widely used for the treatment of diabetes mellitus, while it is still under investigation as a therapy for immune-mediated diseases. In addition, CD26’s involvement in cancer immunology was also described. The review aims to summarize the therapeutic effects of CD26 inhibitors on immune-mediated diseases, as well as the mechanisms that underpin them. |
| first_indexed | 2024-03-09T06:08:45Z |
| format | Article |
| id | doaj.art-c406767550164b48b78b8fa12932ef36 |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-09T06:08:45Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-c406767550164b48b78b8fa12932ef362023-12-03T12:01:43ZengMDPI AGMolecules1420-30492022-07-012714449810.3390/molecules27144498Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated DiseasesXiaopeng Hu0Xisheng Wang1Xingkui Xue2Medical Research Center, People′s Hospital of Longhua, Shenzhen 518109, ChinaMedical Research Center, People′s Hospital of Longhua, Shenzhen 518109, ChinaMedical Research Center, People′s Hospital of Longhua, Shenzhen 518109, ChinaThe enzymatic activity of CD26/DPP4 (dipeptidyl peptidase 4/DPP4) is highlighted in multiple studies to play a vital role in glucose metabolism by cleaving and inactivating the incretins glucagon-like peptide-1 (GLP) and gastric inhibitory protein (GIP). A large number of studies demonstrate that CD26 also plays an integral role in the immune system, particularly in T cell activation. CD26 is extensively expressed in immune cells, such as T cells, B cells, NK cells, dendritic cells, and macrophages. The enzymatic activity of CD26 cleaves and regulates numerous chomokines and cytokines. CD26 inhibitors have been widely used for the treatment of diabetes mellitus, while it is still under investigation as a therapy for immune-mediated diseases. In addition, CD26’s involvement in cancer immunology was also described. The review aims to summarize the therapeutic effects of CD26 inhibitors on immune-mediated diseases, as well as the mechanisms that underpin them.https://www.mdpi.com/1420-3049/27/14/4498CD26/DPP4 inhibitorimmune-mediated diseasesdiabetic cardiovascular diseaseautoimmune diabetesinflammatory bowel disease (IBD)graft-versus-host disease (GVHD) |
| spellingShingle | Xiaopeng Hu Xisheng Wang Xingkui Xue Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases Molecules CD26/DPP4 inhibitor immune-mediated diseases diabetic cardiovascular disease autoimmune diabetes inflammatory bowel disease (IBD) graft-versus-host disease (GVHD) |
| title | Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases |
| title_full | Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases |
| title_fullStr | Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases |
| title_full_unstemmed | Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases |
| title_short | Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases |
| title_sort | therapeutic perspectives of cd26 inhibitors in imune mediated diseases |
| topic | CD26/DPP4 inhibitor immune-mediated diseases diabetic cardiovascular disease autoimmune diabetes inflammatory bowel disease (IBD) graft-versus-host disease (GVHD) |
| url | https://www.mdpi.com/1420-3049/27/14/4498 |
| work_keys_str_mv | AT xiaopenghu therapeuticperspectivesofcd26inhibitorsinimunemediateddiseases AT xishengwang therapeuticperspectivesofcd26inhibitorsinimunemediateddiseases AT xingkuixue therapeuticperspectivesofcd26inhibitorsinimunemediateddiseases |